Erythema multiforme; This spontaneous case was reported by a nurse and describes the occurrence of ERYTHEMA MULTIFORME (Erythema multiforme) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Intestinal ulcer (for over use of ibuprophen), Spinal fusion surgery in 2003, Haemorrhoid operation on 06-Jan-2001 and Hospitalization in 2011. Concurrent medical conditions included Nephrolithiasis since 01-Jan-1984, Colitis, AIDS since 07-May-1995, Migraine ((15-20 migraines per month)/ breakthrough migraines/ chronic migraine without auroa with status not interactable since 6 to years.), HIV infection, Vitamin D deficiency, Sinusitis, Sleep disorder and Joint stiffness. Concomitant products included DICLOFENAC (VOLTAREN [DICLOFENAC]) for Back pain, ASCORBIC ACID, CHONDROITIN SULFATE SODIUM, COLLAGEN, GLUCOSAMINE SULFATE, MANGANESE (COLLAGEN COMPLEX) for Joint stiffness, ERENUMAB (AIMOVIG [ERENUMAB]) for Migraine, RIMEGEPANT SULFATE (NURTEC ODT), TESTOSTERONE (ANDROGEL), DOLUTEGRAVIR SODIUM (TIVICAY), COLECALCIFEROL (D3), VITAMIN B2 [RIBOFLAVIN] and FEVERFEW [TANACETUM PARTHENIUM] for an unknown indication.    In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Sep-2021, the patient experienced ERYTHEMA MULTIFORME (Erythema multiforme) (seriousness criterion medically significant). The patient was treated with EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE (DESCOVY) for HIV infection, at an unspecified dose and frequency; TEMAZEPAM for Sleep disorder, at an unspecified dose and frequency; MOMETASONE FUROATE (NASONEX) (nasal) for Sinusitis, at a dose of 50 mcg; MAGNESIUM OXIDE in 2019 for Migraine, at a dose of 400 mg once a day; VALACICLOVIR HYDROCHLORIDE (VALACYCLOVIR HCL) for Adverse event, at an unspecified dose and frequency and PREDNISONE for Adverse event, at an unspecified dose and frequency. At the time of the report, ERYTHEMA MULTIFORME (Erythema multiforme) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood testosterone: abnormal (abnormal) Blood testosterone Abnormal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient had reported Gastrointestinal disorder and Therapeutic product effect delayed  Company comment: This is a spontaneous case concerning a 60-year-old male patient with medical history of AIDS, receiving erenumab for Migraine and multiple concomitant medications, who experienced the serious unexpected event Erythema multiforme. The event occurred between one and three weeks after the booster dose of mRNA-1273.  AIDS medical history and multiple concomitant medications could be  potential confounder/co-suspects. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 60-year-old male patient with medical history of AIDS, receiving erenumab for Migraine and multiple concomitant medications, who experienced the serious  unexpected event Erythema multiforme. The event occurred between one and three weeks after the booster  dose of mRNA-1273. AIDS medical history and multiple concomitant medications could be  potential confounder/co-suspects. The benefit-risk relationship of mRNA-1273 is not affected by this report.